VANI vs VERU

Vivani Medical, Inc. vs Veru Inc. — Valuation Comparison 2026

VANI

Biotechnology
Vivani Medical, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$1.29
Last close
Models
7/13
Active
VS

VERU

Biotechnology
Veru Inc.
Quality
4.6
out of 10
Value Trap
25
LOW
Price
$2.32
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType VANI Fair ValueVANI Upside VERU Fair ValueVERU Upside
Bayesian DCF Intrinsic $0.39 -70.2% $1.49 -35.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.43 -66.6% $3.71 +60.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for VANI vs VERU — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VANI vs VERU — Which Stock Is More Undervalued?

VERU scores higher with a 4.6/10 quality rating vs VANI's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vivani Medical, Inc. (VANI) and Veru Inc. (VERU) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VANI currently trades at $1.29 with a QOC of 4.4/10, while VERU trades at $2.32 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).